Illumina, Inc.
$188.68+2.6%YTD+40.0%1Y+87.4%
Mentions · last 7 days
111
Price updated 34m ago·X counts updated 23h ago
What it does
Plain-English summary of the business — what they sell and how they make money.
Industry overviewAI analysisGenerated by AI from underlying data
Where Medical - Diagnostics & Research sits in its cycle right now — and what that implies for $ILMN.
Medical - Diagnostics & Research
Life science instrument demand is normalizing after the post-COVID destocking cycle — pharma R&D spending is recovering and CDMO demand is growing as drug pipelines advance toward clinical trials. AI-assisted drug discovery (SDGR, TWST) is creating incremental instrument and data demand on top of the recovery cycle.
Industry benchmark
13-name peer basket
+20.9%YTD
+40.6%1Y
Fundamentals & catalyst
Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.
Key ratios
P/E
33.2How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.ROIC
13.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.Op margin
21.5%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.FCF yield
3.6%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).P/S
6.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.ROE
34.0%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.Gross margin
67.7%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.D/E
1.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.Past earnings
QuarterReportedActualEstimateSurprise
Q1 2026Apr 30, 2026$1.15$1.05+9.5%
Q4 2025Feb 5, 2026$1.35$1.24+8.9%
Q3 2025Oct 30, 2025$1.34$1.17+14.5%
Q2 2025Jul 31, 2025$1.19$1.02+16.7%
Next earningsThu, Jul 30·consensus EPS $1.24
Quarterly trend
QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$1.1B+4.8%68.2%21.3%$0.88$251.0M
Q4 FY25$1.2B+5.1%67.1%22.2%$2.18$267.0M
Q3 FY25$1.1B+0.3%67.6%21.3%$0.98$260.0M
Q2 FY25$1.1B-4.9%67.8%21.0%$1.50$211.0M
Forward consensus
FYRevenueRangeEPSRangeAnalysts
FY26$4.6B$4.6B – $4.6B$5.23$5.16 – $5.2713
FY27$4.8B$4.8B – $4.9B$5.92$5.67 – $6.2513
FY28$5.2B$5.2B – $5.2B$6.81$6.50 – $7.4714
FY29$5.6B$5.5B – $5.6B$7.91$7.80 – $8.047
FY30$5.8B$5.8B – $5.9B$8.85$8.73 – $8.9910
Setup & momentum
Volume, range, and moving-average position — the technical setup driving short-term moves.
Right now
Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.99%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+21.1%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+41.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.
Float & profile
FloatMid float · 148.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.4% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.
Insider activity
Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.
Recent news
Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.
More in Medical - Diagnostics & Research
Peers in the same group — one click to compare setups, fundamentals, and chatter.
Voices on X · last 7 days
No standout posts about $ILMN on X in the last 7 days.